Theraclion bags €8.5m for parathyroid disorder therapy
This article was originally published in Clinica
Executive Summary
Theraclion is advancing clinical trials of its ultrasound-based noninvasive surgical system for treating hyperparathyroidism after securing €8.5m ($11m) from the French innovation agency, OSEO. Paris-based Theraclion is developing its technology together with SuperSonic Imagine, a fellow French ultrasound specialist. €1.6m of the new funds will go to the latter, so that it can develop its Aixplorer product for integration into Theraclion's system. The Aixplorer will provide high resolution ultrasound imaging and elastographic information to enable doctors to locate and identify the affected tissue nodule, while Theraclion's technology will use high intensity focused ultrasound to coagulate the tissue. The out-patient procedure takes around 30 minutes and will provide a simple, noninvasive, lower cost alternative to current methods of treating hyperparathyroidism, said Paris-based Theraclion. Hyperparathyroidism is the overactivity of the parathyroid glands – the potential market for primary hyperparathyroidism alone is worth over €300m, according to Theraclion.